Mayne Pharma Group (AU:MYX) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Mayne Pharma Group has announced a significant change in the securities interest of its director, Shawn Patrick O’Brien. As of December 2, 2024, O’Brien acquired an additional 301,455 Performance Rights and 35,170 RSU Performance Rights, increasing his direct holdings. This change reflects O’Brien’s growing stake in the company, potentially signaling confidence in Mayne Pharma’s future performance.
For further insights into AU:MYX stock, check out TipRanks’ Stock Analysis page.
